scholarly journals Serum calcitonin measurement for screening of medullary thyroid cancer: A systematic review

2017 ◽  
Vol 3 (1) ◽  
pp. 2-3
Author(s):  
Ahmadreza Zarifian ◽  
Ramin Sadeghi ◽  
Zohreh Mousavi
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Serum Calcitonin ◽  
Medullary Thyroid

scholarly journals SUN-LB82 Coexistence of Medullary Thyroid Cancer With Graves Disease: A Case Report

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Ogochukwu Okoli ◽  
Christine A Resta
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Case Report ◽  
Thyroid Gland ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Cancer ◽  
Graves Disease ◽  
Serum Calcitonin ◽  
Medullary Thyroid

Abstract A 59 year old woman presented with enlarged thyroid, weight loss, and hot flushes. She had previously been treated for a thyroid problem in 2013 but was lost to follow up. On exam, she had a diffusely enlarged thyroid gland, without distinct nodule. She had brisk DTR’s and mild tremor. Lab results confirmed hyperthyroidism:TSH <0.01 mIU/L (0.27 to 4.2) FT4 2.4 ng/dL (0.9 to 1.8) FT3 7.95 pg/mL (1.8 to 4.6). TSI was 307 % (<140%). Thyroid ultrasound showed a few sub-centimeter nodules, and 2 clinically significant nodules on the right--1.5 x 1.2 x 1.4 cm, cystic with calcifications; and 1.3 x 0.7 x 1.2 cm hypoechoic. I-123 thyroid uptake/scan showed 61% uptake and 2 right sided cold nodules. FNA biopsy showed medullary thyroid carcinoma (MTC) with staining positive for calcitonin and negative for thyroglobulin. CT thyroid showed no adenopathy. Serum calcitonin was 71 pg/mL (<5), and CEA was elevated 5.4 ng/mL (<2.5). Work up was negative for pheochromocytoma and hyperparathyroidism.After pretreatment with methimazole, she underwent total thyroidectomy with bilateral TE groove dissection. Surgical pathology confirmed MTC pT1b pN1a. She was started on levothyroxine therapy post operatively. Discussion There are multiple reports of thyroid carcinoma (papillary and follicular) in Graves disease, but rarely MTC.1 A recent systematic review reports only 21 total cases of MTC in patients with hyperthyroidism, of whom 15 had Graves disease.2 MTC is derived from C-cells from the thyroid gland rather than from follicular cells. TSI, therefore, should not influence development or growth of MTC. Coexistence of the two conditions is likely coincidental rather than causative. ConclusionThyroid nodules in patients with Graves should be worked up as there is a possibility of co-existing thyroid carcinoma. This patient had hyperthyroidism with cold nodules on nuclear scan corresponding to sonographic nodules. Based on these results, she had biopsy leading to diagnosis of MTC. Follow up surgery lead to diagnosis of MTC at earlier stage and provided treatment for both conditions. References1. Staniforth, J. U. etal (2016). Thyroid carcinoma in Graves’ disease: a meta-analysis. International Journal of Surgery, 27, 118-125. 2. Sapalidis, K. etal (2019). A Rare Coexistence of Medullary Thyroid Cancer with Graves Disease: A Case Report and Systematic Review of the Literature. The American journal of case reports, 20, 1398

scholarly journals Surgical approach to medullary thyroid cancer

2007 ◽  
Vol 51 (5) ◽  
pp. 818-824 ◽  
Author(s):  
Catharina Ihre Lundgren ◽  
Leigh Delbridg ◽  
Diana Learoyd ◽  
Bruce Robinson
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Medullary Thyroid Cancer ◽  
Prophylactic Surgery ◽  
Surgical Removal ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Central Lymph Node Dissection ◽  
Familial Form ◽  
Men 2A

Medullary thyroid cancer (MTC) compromises 3-5% of all thyroid cancers and arises from parafollicular or calcitonin-producing C cells. It may be sporadic (75% of cases), or may occur as a manifestation of either the hereditary syndrome Multiple Endocrine Neoplasia type 2 (MEN 2A or MEN 2B) (25% of cases), or rarely as an isolated familial syndrome (FMTC). Complete surgical resection comprising in most cases total thyroidectomy with central lymph node dissection at an early stage of the disease is the only potential cure for MTC. The familial form of the disease, MEN-2A occupies a unique place in surgical history, having been the first disease where surgical removal of an affected organ was undertaken before the development of malignancy, solely on the basis of genetic testing. Total thyroidectomy prior to the development of invasive cancer completely avoids an otherwise lethal malignancy. Timing of prophylactic surgery is based on models that utilise genotype-phenotype correlations, which have now been stratified into three risk groups based on the specific codon involved. MTC should be followed with postoperative serial serum calcitonin levels to survey for persistent or recurrent disease as indicated by detectable levels. The challenge however, if calcitonin levels are increased, is to find the source of its production. The first localisation technique recommended would be ultrasound of the neck, since there is a high frequency of local recurrence and cervical node metastasis, followed by a total body CT scan and bone scintigraphy.

Serum Calcitonin May Falsely Estimate Tumor Burden in Chronic Hypercalcemia: A Case of Prostatic and Multiple Bone Metastases from Medullary Thyroid Cancer

Thyroid ◽  
2014 ◽  
Vol 24 (3) ◽  
pp. 599-603 ◽  
Author(s):  
Hee Kyung Kim ◽  
Woo Kyun Bae ◽  
Yoo Duk Choi ◽  
Hyun Jeong Shim ◽  
Jee Hee Yoon ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Medullary Thyroid Cancer ◽  
Tumor Burden ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Multiple Bone Metastases

scholarly journals Tumor cells may circulate in medullary thyroid cancer patients independently of serum calcitonin

2018 ◽  
Vol 25 (12) ◽  
pp. L59-L63 ◽  
Author(s):  
Sathya Neelature Sriramareddy ◽  
Etienne Hamoir ◽  
Marcela Chavez ◽  
Renaud Louis ◽  
Albert Beckers ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Medullary Thyroid Cancer ◽  
Serum Calcitonin ◽  
Medullary Thyroid

Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits

2015 ◽  
Vol 34 (6) ◽  
pp. 378-382 ◽  
Author(s):  
M.R. Pelizzo ◽  
F. Torresan ◽  
A. Da Roit ◽  
I. Merante Boschin ◽  
S. Chondrogiannis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Moderate Increase ◽  
Serum Calcitonin ◽  
Medullary Thyroid

scholarly journals Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5842
Author(s):  
Jinyoung Kim ◽  
Jun Park ◽  
Hyunju Park ◽  
Min Sun Choi ◽  
Hye Won Jang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Medullary Thyroid Cancer ◽  
Lymph Node Ratio ◽  
Serum Calcitonin ◽  
Free Survival ◽  
Medullary Thyroid ◽  
Node Ratio ◽  
Postoperative Serum

The lymph node ratio (LNR) has been investigated as a prognostic factor in many different types of cancers, including differentiated thyroid cancer; however, reports regarding medullary thyroid cancer (MTC) are limited. Therefore, this study aims to evaluate LNR as a risk factor for structural recurrence in patients with MTC. Medical records of patients treated for MTC in a single tertiary center between 1995 and 2017 were retrospectively reviewed. LNR is defined as the number of metastatic lymph nodes or lymph node metastases (LNM) divided by the number of retrieved lymph nodes or lymph node yield (LNY). In the survival analysis, recurrence-free survival was defined as the time from the date of total thyroidectomy to recurrence or last follow-up. To identify risk factors influencing structural recurrence, univariable and multivariable Cox proportional hazard models were used. A total of 132 patients were enrolled. The mean age of study participants was 49.7 years, and 86 patients (65%) were women. Structural recurrence was identified in 39 patients at the end of the study period, and the median follow-up period was 8.7 years. In univariable analyses, gross extra thyroidal extension, N stage, postoperative serum calcitonin and carcinoembryonic antigen (CEA) levels, and LNR were significant (p < 0.05) predictors of structural recurrence. In multivariable analysis, postoperative serum calcitonin, postoperative serum CEA, and LNR were identified as a predictor of disease-free survival (p < 0.05). LNR can potentially predict structural recurrence as a quantitative evaluation tool for lymph node metastasis in patients with MTC.

Sign in / Sign up

Export Citation Format

Share Document